Clinical Protocol and Data Management
Clinical Protocol and Data Management
批准号:
9923044
负责人:
ANNE M TRAYNOR
金额:
$30.82万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AchievementAmericanAppointmentBudgetsBusinessesCancer CenterCancer Center Support GrantClinicClinical DataClinical ManagementClinical ProtocolsClinical ResearchClinical TrialsCommunitiesComprehensive Cancer CenterConduct Clinical TrialsConsentData Management ResourcesData ReportingDevelopmentDreamsEnsureFacultyFundingGrantHealthHealth SciencesIndustrializationInformaticsInfrastructureInstitutionInstitutional Review BoardsInterventionIntervention TrialInvestmentsLeadLeadershipMalignant Childhood NeoplasmMinorityMissionMonitorMultilingualismNCI Center for Cancer ResearchNational Comprehensive Cancer NetworkOncologyOutpatientsPatient CarePatientsPeer ReviewPerformancePharmacologic SubstancePoliciesProceduresProtocols documentationQuality ControlRegulationReportingResearchResearch ActivityResearch PersonnelResource SharingRiskServicesSiteStructureSystemTherapeutic InterventionTimeTraining and EducationWisconsinWomanadjudicateanticancer researchbasecancer health disparitycancer therapyclinical careclinical infrastructuredata managementdata qualityimprovedindustry partnerinnovationmemberoutreachquality assuranceresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – CLINICAL PROTOCOL AND DATA MANAGEMENT
The Clinical Research Central Office (CRCO) provides the centralized infrastructure for clinical research
activities at the UW Carbone Cancer Center (UWCCC). The CRCO includes 87 FTEs who support 244 faculty
PIs with an annual operating budget of $6.4M; annual CCSG provides $248K (directs) of the total CRCO budget.
Under the leadership of Center Director Dr. Howard Bailey and Associate Director for Clinical Research, Dr.
Ruth O’Regan (DT), UWCCC has significantly expanded and centralized the CRCO infrastructure, supported
by a $2M investment (non-CCSG) by Dr. Bailey in new annual operating funds. Restructuring has yielded
expertise and efficiencies in central administration, study coordination, patient care, regulatory, fiscal,
informatics, quality assurance, billing compliance, and educational teams. In 2016, the CRCO supported accrual
of 2,582 subjects to 257 research studies across the center. Of the 165 treatment intervention clinical trials in
2016, the sponsor breakdown was as follows: Externally peer reviewed (14 studies, or 8%), Industrial (54, or
33%), Institutional (23, or 14%), and National (74, or 45%). Promising early results of centralization include the
reversal in 2016 of a 7-year decline in treatment intervention accrual, improvement in study activation metrics,
and reduced CRCO staff turnover. The CRCO supports clinical research conducted on site, through NCTN and
ETCTN, through our statewide IIT network Wisconsin Oncology Network (WON), and through our memberships
in the Big Ten Cancer Research Consortium (BTCRC) and National Comprehensive Cancer Network (NCCN),
with whom we are collaborating and developing new IITs. Research Informatics has expanded, led by a newly
hired Assistant Director, Business Analyst, CTMS manager, and a revised OnCore® Support Team, increasing
our eCRF development 7-fold. The QA/Compliance team executes our DSMP, enacting risk-based monitoring,
determined by study sponsorship and PRMC-adjudicated risk level. Monitoring, auditing, and data quality and
assurance reviews include Internal Audits, Compliance Reviews, and Review of SAE reporting. The CRCO has
initiated multiple new initiatives to improve our accrual of women and minorities to clinical trials, including wider
interactions with the UWCCC Cancer Health Disparities Initiative, increasing support of translator and multi-
lingual consenting services, and targeted, multi-culturally appropriate media outreach efforts. The CRCO
envisions continued expansion via vigorous support from the UWCCC and industry partnerships, enabling an
increasing percentage of our patients’ access to innovative and impactful clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PILOT STUDY OF LIQUID CRYSTAL NANO-STRUCTURED SURFACES (LC/NS) ANALYSES
-
批准号:7607518
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2006
-
负责人:ANNE M TRAYNOR
-
依托单位:
PHASE II STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN RELAPSED NSCLC
-
批准号:7607543
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2006
-
负责人:ANNE M TRAYNOR
-
依托单位:
Phase II Trial of PS341/Dox in Metastatic Breast Cancer
-
批准号:7027074
-
项目类别:
-
资助金额:$16.99万
-
财政年份:2005
-
负责人:ANNE M TRAYNOR
-
依托单位:
PHASE II STUDY OF INTERLEUKIN 12 FOR PLATEAU PHASE MULTIPLE MYELOMA
-
批准号:6304154
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1999
-
负责人:ANNE M TRAYNOR
-
依托单位:
INFUSIONAL 8 CHLORO CYCLIC AMP IN TREATMENT OF MULTIPLE MYELOMA
-
批准号:6263949
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:ANNE M TRAYNOR
-
依托单位:
STEM CELL TRANSPLANT AS STANDARD TREATMENT FOR MULTIPLE MYELOMA
-
批准号:6263974
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:ANNE M TRAYNOR
-
依托单位:
PHASE II STUDY OF INTERLEUKIN 12 FOR PLATEAU PHASE MULTIPLE MYELOMA
-
批准号:6263964
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:ANNE M TRAYNOR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10456708
-
项目类别:
-
资助金额:$28.96万
-
财政年份:1997
-
负责人:ANNE M TRAYNOR
-
依托单位:
INFUSIONAL 8 CHLORO CYCLIC AMP IN TREATMENT OF MULTIPLE MYELOMA
-
批准号:6304139
-
项目类别:
-
资助金额:$2.05万
-
财政年份:--
-
负责人:ANNE M TRAYNOR
-
依托单位:
海外基金